Identification of Potential Therapeutic Agents for Type I Interferonopathy Using iPSC-Based Disease Modeling
Our iPSC-based disease modeling and drug investigation approach provides a robust platform for validating the efficacy and toxicity of candidate therapeutic agents for rare and intractable human diseases such as type I interferonopathy.
Authors
- Hirofumi Shoda (ORCID: https://orcid.org/0000-0002-1536-0303)
- Makoto Otsu (ORCID: https://orcid.org/0000-0002-9769-0217)
- Bunki Natsumoto (ORCID: https://orcid.org/0000-0003-4354-3972)
- Keishi Fujio (ORCID: https://orcid.org/0000-0001-7276-5254)
- Motonori Tsuji (ORCID: https://orcid.org/0000-0003-0734-0334)
- Kazuhiko Yamamoto (ORCID: https://orcid.org/0000-0001-9037-3625)
- Hideki Taniguchi (ORCID: https://orcid.org/0000-0002-6186-9266)
Institutions
- Tokyo University of Science (JP)
- Tokyo Medical University Hospital (JP)
- RIKEN Center for Integrative Medical Sciences (JP)
- Kitasato University (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Journal of Clinical Immunology
- Published
- 2025-09-30
- DOI
- https://doi.org/10.1007/s10875-025-01933-8
- Primary Topic
- CRISPR and Genetic Engineering
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Agency for Medical Research and Development
- Ministry of Education, Culture, Sports, Science and Technology
- University of Tokyo
- Japan Society for the Promotion of Science
- Institute of Medical Science, University of Tokyo